Shaw & Co has advised Nanopharm Limited on its sale to AptarGroup, Inc. The acquisition is part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers accelerate and derisk their complex product developments.

Nanopharm brings complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.

Located in Newport, UK, Nanopharm is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. The business employs 37 people at its state-of-the-art analytical facility.

“We are delighted to welcome the talented team at Nanopharm and their customers to Aptar Pharma,” commented Gael Touya, President of Aptar Pharma. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”

Stephan Tanda, President and CEO, stated, “This strategic investment further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our services offerings. Nanopharm, a leader in inhalation and nasal drug development services is complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”

Nanopharm Founder and Chief Scientific Officer Prof. Robert Price said “In Aptar we have found the ideal partner to continue the successful growth of Nanopharm. Aptar is perfectly positioned to support the development of our science driven, solution-oriented services for inhalation and nasal drug products. This exciting new chapter in our development will allow us to deliver yet more as we leverage Aptar’s expertise and infrastructure to better serve our highly-valued clients.”

"
We are extremely grateful to Shaw & Co for all their help and guidance. Their stellar team were absolutely critical to delivering this great result. "

Professor Robert Price
Chief Scientific Officer at Nanopharm

‍

Chief Executive Officer Dr. Jag Shur added “Our decision to join forces with Aptar Group has been made very carefully indeed. This synergistic partnership and shared commitment to scientific excellence, will enable us to better serve our clients by offering a broader spectrum of innovative solutions and enhance our level of technical services going forward. The future of Nanopharm as part of the Aptar Group is very exciting indeed.”

Both Prof. Price and Dr. Shur will continue in their roles at Nanopharm post acquisition.

Legal advice was provided to the shareholders of Nanopharm by Burges Salmon.

‍